Vertebrobasilar insufficiency
Methodology & AI Transparency ⓘ
Vertebrobasilar insufficiency Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Designated in federal medical registries as G45.0, Vertebrobasilar insufficiency falls under Brain & Neurology management, where CSF/autoimmune antibody panels in Vertebrobasilar insufficiency (G45.0: when indicated) establishes baseline severity and rules out diagnostic mimics.
- 2 Real-world patient consensus: Clinical coding for Vertebrobasilar insufficiency uses ICD-10 G45.0 across Brain & Neurology specialty care.
- 3 Typical cash cost range: Workup highlights for Vertebrobasilar insufficiency (G45.0): CSF/autoimmune antibody panels in Vertebrobasilar insufficiency (G45.0: when indicated).
- 4 Top reported side effects / signs: Follow-up benchmark in Vertebrobasilar insufficiency: maintaining Carotid Duplex / in Vertebrobasilar insufficiency (G45.0: Cerebral Perfusion) within No hemodynamically significant stenosis (G45.0).
Ask our AI Specialists anything about Vertebrobasilar insufficiency
What Is Vertebrobasilar insufficiency?
Designated in federal medical registries as G45.0, Vertebrobasilar insufficiency falls under Brain & Neurology management, where CSF/autoimmune antibody panels in Vertebrobasilar insufficiency (G45.0: when indicated) establishes baseline severity and rules out diagnostic mimics.
Pathophysiology, Underlying Causes & Clinical Presentation
Underlying Vertebrobasilar insufficiency (code G45.0) is synaptic transmission alteration [Vertebrobasilar insufficiency G45.0], which Neurology, Stroke & Movement Disorders clinicians address while surveilling Carotid Duplex / in Vertebrobasilar insufficiency (G45.0: Cerebral Perfusion) (No hemodynamically significant stenosis (G45.0)).
Common Symptoms & Clinical Signs
- • Presentation of Vertebrobasilar insufficiency (G45.0): muscle stiffness, spasticity, in Vertebrobasilar insufficiency (G45.0: or fatigable neuromuscular)
- • Secondary Vertebrobasilar insufficiency clinical sign: focal motor weakness, in Vertebrobasilar insufficiency (G45.0: resting or action)
- • Symptom flares in Vertebrobasilar insufficiency correlating with Carotid Duplex / in Vertebrobasilar insufficiency (G45.0: Cerebral Perfusion) deviation outside No hemodynamically significant stenosis (G45.0)
- • Functional brain & neurology impact requiring CSF/autoimmune antibody panels in Vertebrobasilar insufficiency (G45.0: when indicated) evaluation (G45.0)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Vertebrobasilar insufficiency Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | G45.0 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Neurology, Stroke & Movement Disorders | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Carotid Duplex / in Vertebrobasilar insufficiency (G45.0: Cerebral Perfusion) | No hemodynamically significant stenosis (G45.0) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: HbA1c & Blood in Vertebrobasilar insufficiency (G45.0: Pressure Neuro-Targets) | BP < 120/75 mmHg; HbA1c < 5.7% (G45.0) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Serum Vitamin B12 in Vertebrobasilar insufficiency (G45.0: & Methylmalonic Acid) | B12 > 500 pg/mL; MMA < 240 nmol/L (G45.0) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Vertebrobasilar insufficiency
Treatment selection for Vertebrobasilar insufficiency depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Vertebrobasilar insufficiency)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Consent-Related Outcomes in the Alteplase Compared to Tenecteplase: What a 1,600-Participant Study Found The AcT trial enrolled 1,600 participants from 22 centers across Canada of whom 1,537 were enrolled through deferral of consent (96.0%) and 63 (4.0%) were enrolled by prospective verbal consent followed by written informed... Neurology • 2024-11-26 • Phase III Randomized Trial | N = 1,600 | 90/100 | PMID 39509663 ↗ |
| Can This Approach Help? Inside the Latest Research on Establishing minimally clinically important differences for the orthostatic These MCID thresholds for the OHQ, OHSA and OHSA item 1 alone, enhance the interpretability of scores and support their use in evaluating clinical benefit. Clinical autonomic research : official journal of the Clinical Autonomic Research Society • 2026-02-15 • Phase III Randomized Trial | N = 184 | 88/100 | PMID 41134458 ↗ |
| New Insights on Benefits and safety of Recombinant Human Prourokinase in the Treatment of Acute: What a 684-Participant Study Found Among 663 patients in the modified intention-to-treat population (mean [SD] age, 61.00 [10.20] years; 161 females [24.3%]), there were 330 patients in the rhPro-UK group and 333 patients in the alteplase group. JAMA network open • 2023-07-03 • Phase III Randomized Trial | N = 684 | 87/100 | PMID 37490291 ↗ |
| What the Latest Evidence Really Says About Potential Locations for Noninvasive Brain Stimulation in Treating Poststroke This multimodal approach systematically identified precise NIBS targets, confirming established sites and revealing novel regions to broaden neuromodulation strategies for poststroke recovery. CNS neuroscience & therapeutics • 2026-11-15 • Meta-Analysis | Multi-cohort | 86/100 | PMID 42953957 ↗ |
| Can This Approach Help? Inside the Latest Research on Tenecteplase versus standard care in patients with acute basilar artery Safety outcomes are symptomatic intracranial haemorrhage within 36 hours, death within 90 days and mRS 5-6 at 90 days. Stroke and vascular neurology • 2026-06-29 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 41151803 ↗ |
Vertebrobasilar insufficiency Patient Community & “People Like Me” Threads
Filter Vertebrobasilar insufficiency community threads and patient logs by age, biological sex, dosage, and treatment duration.